Compare PLBC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | PRTC |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.7M | 400.2M |
| IPO Year | 2002 | N/A |
| Metric | PLBC | PRTC |
|---|---|---|
| Price | $50.46 | $17.11 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $57.67 | N/A |
| AVG Volume (30 Days) | ★ 52.8K | 6.7K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $11.28 | ★ $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.70 | $14.50 |
| 52 Week High | $54.58 | $19.92 |
| Indicator | PLBC | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 48.92 |
| Support Level | $40.58 | $16.51 |
| Resistance Level | $52.61 | $18.34 |
| Average True Range (ATR) | 1.30 | 0.63 |
| MACD | -0.17 | -0.05 |
| Stochastic Oscillator | 6.49 | 6.72 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.